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Abstract
Because caffeine may induce cyst and kidney enlargement in autosomal dominant polycystic kidney disease (ADPKD), we 
evaluated caffeine intake and renal volume using renal ultrasound in ADPKD patients. Caffeine intake was estimated by the 
average of 24-h dietary recalls obtained on 3 nonconsecutive days in 102 ADPKD patients (68 females, 34 males; 39 ± 12 
years) and compared to that of 102 healthy volunteers (74 females, 28 males; 38 ± 14 years). The awareness of the need for 
caffeine restriction was assessed. Clinical and laboratory data were obtained from the medical records of the patients. Mean 
caffeine intake was significantly lower in ADPKD patients versus controls (86 vs 134 mg/day), and 63% of the ADPKD patients 
had been previously aware of caffeine restriction. Caffeine intake did not correlate with renal volume in ADPKD patients. There 
were no significant differences between the renal volumes of patients in the highest and lowest tertiles of caffeine consumption. 
Finally, age-adjusted multiple linear regression revealed that renal volume was associated with hypertension, chronic kidney 
disease stage 3 and the time since diagnosis, but not with caffeine intake. The present small cross-sectional study indicated a 
low level of caffeine consumption by ADPKD patients when compared to healthy volunteers, which was most likely due to prior 
awareness of the need for caffeine restriction. Within the range of caffeine intake observed by ADPKD patients in this study 
(0-471 mg/day), the renal volume was not directly associated with caffeine intake.
Key words: Polycystic kidneys; ADPKD; Cyclic AMP; Caffeine; Nutrition; Renal volume 
Introduction
www.bjournal.com.brBraz J Med Biol Res 45(9) 2012
Correspondence: I.P. Heilberg, Disciplina de Nefrologia, Departamento de Medicina, UNIFESP, Rua Botucatu, 740, 04023-900 
São Paulo, SP, Brasil. Fax: +55-11-5904-1684. E-mail: ipheilberg@nefro.epm.br
Received December 7, 2011. Accepted July 4, 2012. Available online July 20, 2012. Published August 17, 2012.
Autosomal dominant polycystic kidney disease (ADPKD) 
is the most common inherited renal cystic disease and is 
characterized by the development of renal cysts and various 
extrarenal manifestations. A disruption of normal polycystic 
function by mutations in polycystic kidney disease 1 (PKD1) 
or polycystic kidney disease 2 (PKD2) genes predisposes 
the individual to cyst formation through the loss of mechani-
cal cues in the tubular epithelial cells that regulate tissue 
morphogenesis (1). 
ADPKD patients may remain asymptomatic for years 
or present signs and symptoms of flank pain, hematuria, 
urinary tract infections, hypertension and nephrolithiasis (2). 
Multiple cysts generally increase in size and number with 
age, ultimately resulting in end-stage renal disease. Mag-
netic resonance imaging (MRI) data from an observational 
trial of ADPKD showed that kidney volume increases by an 
average of 5.3% per year but with a wide range of variabil-
ity, and that renal volume can be used to monitor disease 
progression before a measurable decline in function (3).
Currently, there are no established treatments to slow 
the progression of the disease, but several promising thera-
peutic options are being tested in ongoing clinical trials (1). 
Arginine vasopressin (AVP) is the major stimulus that leads 
to an increase in intracellular cyclic adenosine monophos-
phate (cAMP) levels in cyst epithelial cells, contributing 
to cyst and kidney enlargement (1). The administration of 
AVP V2 receptor antagonists inhibits the development of 
polycystic kidney disease in animal models, and clinical 
studies have been initiated with Tolvaptan (4). Similarly, 
suppressing AVP release with high water intake is protec-
tive in rats (5) and is a promising alternative approach in 
humans (6).
Receptor-mediated agents that increase the activity of 
adenyl cyclase and inhibitors of phosphodiesterase (PDE) 
such as caffeine, a 1,3,7-trimethylxanthine (7), have the 
potential to accelerate the progression of ADPKD. In a very 
elegant experimental study conducted by Belibi et al. (8), 
a V2 receptor agonist (DDAVP) increased the intracellular 
Caffeine intake and ADPKD 835
www.bjournal.com.br Braz J Med Biol Res 45(9) 2012
levels of cAMP in the cyst epithelial cells, and this effect was 
further increased by caffeine concentrations in a clinically 
relevant range. Subsequently, chronic caffeine administra-
tion to Han:SPRD rats was shown to exacerbate hyperten-
sion in this animal model, but no effect was observed on 
glomerular filtration rate (GFR) or cyst development (9). 
Although it has been recommended that ADPKD patients 
reduce their caffeine intake based on these findings, studies 
in humans are needed.
In the present study, we determined the consumption 
of caffeine by ADPKD patients through 24-h dietary recalls 
and discriminated among its various dietary sources. In 
addition, we sought associations between caffeine intake 
and clinical and laboratory data. 
Material and Methods
A total of 102 adult patients evaluated at the Nephrology 
Division of Universidade Federal de São Paulo, who had a 
diagnosis of ADPKD because of an affected parent or sibling 
with ADPKD and renal cysts detected by ultrasound using 
the diagnostic criteria of Pei et al. (10), were selected to 
participate in the study. One hundred and two age-matched 
healthy volunteers with similar body mass indexes (BMIs) 
were recruited as controls. The Local Ethics Committee 
approved the study and written informed consent was 
obtained from all participants. 
Assessment of dietary habits and anthropometric 
parameters
All participants were submitted to anthropometric as-
sessment that included body weight and height measure-
ments, as well as BMI calculation as weight (kg)/height (m2). 
A complete investigation of nutrient consumption, including 
caffeine, was conducted using a 24-h dietary recall (24R) 
on three nonconsecutive days (2 weekdays and 1 weekend 
day). The average of these 24R was used as an estimate of 
the intake. A trained interviewer (one of the authors, LCV) 
collected the food intake data and showed visual aids to 
assist the participants in estimating the amount consumed. 
Following the last 24R, the ADPKD patients were asked 
whether they had ever read or heard (from health care 
practitioners, friends, relatives, or patients with the same 
disease) about any dietary advice for polycystic kidney 
disease. To avoid suggestibility, only patients who spontane-
ously answered, “Yes, I’ve read or been told to reduce my 
intake of caffeine-containing foods”, were considered to be 
“aware”. All others were classified as “unaware”. The daily 
energy and macronutrient intakes were calculated with a 
computerized program developed in our department. The 
food composition table used in the program was from the 
US Department of Agriculture. Caffeine intake was calcu-
lated according to data from Camargo et al. (11,12), which 
quantified the caffeine content in Brazilian food, including 
coffee (instant, brewed and espresso), regular or diet soft 
drinks (cola or guarana), teas (yerba mate and black) and 
chocolate bars (dark, white and semi-sweet), as shown in 
Table 1. Because the protein intake or ash content of the 
diet may accelerate the course of ADPKD (13), the potential 
renal acid load (PRAL), an established method for estimat-
ing the acid load of diets, was determined according to the 
protein, phosphorus, magnesium, potassium, and calcium 
dietary contents using the formula proposed by Frassetto 
et al. (14).
Clinical and laboratory parameters were obtained from 
the medical records of ADPKD patients. Hypertension was 
considered to be present on the basis of a history of hyper-
tension, blood pressure measurements and use of antihy-
pertensive medications. The renal volume was measured 
by ultrasound and calculated based on kidney length, width 
and anteroposterior diameter using a modified ellipsoid 
formula (15). The values for both kidneys were combined 
to yield the total kidney volume (3). Serum creatinine was 
determined using a modified Jaffé reaction (16) and a Hi-
tachi 912 analyzer (Roche Diagnostic System, Switzerland) 
based on an isotope dilution mass spectrometry-traceable 
method. The estimated GFR (eGFR) was obtained us-
ing the re-expressed, four-variable modification of diet in 
renal disease (MDRD) study equation (13). The stages 
of chronic kidney disease (CKD) were defined according 
to KDIGO (Kidney Disease: Improving Global Outcomes) 
guidelines (17). 
Statistical analysis
Parametric variables are reported as means ± SD 
and nonparametric variables as medians and interquartile 
ranges. The control and ADPKD groups were compared 
by the t-test. Caffeine intake was divided into tertiles. The 
clinical and laboratory parameters were compared by one-
way analysis of variance (ANOVA) or the chi-square test 





Coffee (espresso) 1 cup (60 mL) 59.8
Coffee (instant) 1 cup (60 mL) 44.1
Coffee (brewed) 1 cup (60 mL) 36.5
Black tea 1 cup (150 mL) 34.6
Cola soft drinks 1 can (350 mL) 30.9
Semisweet chocolate 1 bar (30 g) 26.4
Dark sweet chocolate 1 bar (30 g) 11.4
Yerba mate tea 1 cup (150 mL) 10.3
White chocolate 1 bar (30 g) 5.7
Chocolate powder 1 tablespoon 3.7
Guarana soft drinks 1 can (350 mL) 3.8
Data taken from Camargo et al. (11,12).
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(categorical variables). Pearson’s correlation coefficient 
was used to determine the correlation between caffeine 
intake and renal volume or eGFR (unadjusted and adjusted 
for age). A univariate linear analysis was used to reduce 
the pool of variables entered into the multiple regression 
analysis. The independent variables were age, caffeine 
intake, time since diagnosis, presence of hypertension, CKD 
stages 1/2 or stage 3, dietary protein intake, and PRAL. A 
stepwise multiple linear regression analysis adjusted for 
age was performed to describe the association between 
the renal volume or eGFR and the statistically significant 
explanatory variables in the model. For the purpose of this 
analysis, because of the absence of a normal distribution, 
the renal volume, eGFR, caffeine intake, protein, and time 
since diagnosis were converted to a logarithmic (log10) 
scale. The level of significance was set at P < 0.05. 
Results
A total of 102 ADPKD patients (68 women and 34 men) 
and 102 healthy individuals (74 women and 28 men) partici-
pated in this study. Table 2 shows that ADPKD and control 
groups did not differ in mean age, BMI or daily intakes of 
energy, proteins, carbohydrates, and lipids. The mean PRAL 
values did not differ significantly between the ADPKD and 
control groups. However, the mean caffeine intake was 
significantly lower in ADPKD patients than in controls (86 
± 77 vs 134 ± 116 mg/day, P ≤ 0.001). As shown in Table 
3, coffee most commonly contributed to the caffeine intake 
in all groups, followed by soft drinks, chocolate products 
and teas. There was no correlation between the level of 
caffeine intake and renal volume (r = 0.127; P = 0.200) or 
eGFR (r = 0.07; P = 0.445) in the entire sample of ADPKD 
patients. The lack of a correlation between caffeine intake 
and renal volume (r = 0.015; P = 0.879) or eGFR (r = 0.065; 
P = 0.520) persisted even after adjusting for age, as depicted 
in Figure 1A and B.
The clinical and laboratorial characteristics of ADPKD 
patients according to the tertiles of caffeine consumption 
are presented in Table 4. The age, time since diagnosis, 
level of renal function, percentage of hypertensive patients, 
and renal volume did not differ significantly across the 
tertiles of caffeine intake. Sixty-four of the 102 ADPKD 
patients were considered to have been previously aware 
of the need for caffeine restriction. The unaware ADPKD 
patients consumed significantly more caffeine than the 
aware patients (113 ± 92 vs 69 ± 60 mg/day, P = 0.001). 
Because a formal recommendation for caffeine restriction 
had not been given to the present series, we estimated 
the time of prior medical care provided by either a general 
practitioner or a nephrologist. Although there was a trend 
towards a higher prevalence of aware patients (82%) with 
a longer mean estimated time of medical follow-up (39.5 
± 24 months) among the patients in the first tertile of caf-
feine intake (0-41.6 mg), there was no significant difference 
when compared to the percentage of aware patients and 
their respective mean time of medical follow-up within the 
second (56%) and third (50%) tertiles (29.5 ± 22.5 and 
29.8 ± 23 months). 
In a separate analysis of a small number of patients 
(N = 17) whose medical records contained an additional 
ultrasound obtained at the time of diagnosis of PKD, we 
observed a 32% mean increase in renal volume, and the 
median values were significantly different (559.6 vs 307.4 
mL, P < 0.001) between the two ultrasounds (mean interval 
of 49 ± 19 months). However, when this small fraction of 
patients was classified according to a caffeine consump-
tion above or below the median caffeine consumption level 
(85.9 mg/day), the patients who consumed less than 85.9 
mg/day (N = 8) did not show a significant difference in the 
mean percentage of increment of renal volume compared 
to patients with a caffeine consumption ≥85.9 mg/day (N 






Gender (F/M) 74/28 68/34
Age (years) 38 ± 14 39 ± 12
BMI (kg/m2) 24.8 ± 4.8 25.7 ± 4.5
Energy (kcal/day) 1966 ± 601 2018 ± 608
Protein intake (g·kg-1·day-1) 1.2 ± 0.3 1.2 ± 0.4
PRAL (mEq/day) 20 ± 14 21 ± 14
Carbohydrate intake (g/day) 246 ± 78 268 ± 82
Lipid intake (g/day) 70 ± 26 68 ± 25
Caffeine intake (mg/day) 134 ± 116 86 ± 77*
Data are reported as means ± SD. ADPKD = autosomal domi-
nant polycystic kidney disease patients; BMI = body mass index; 
PRAL = potential renal acid load. *P = 0.001 compared to con-
trols (t-test).
Table 3. Mean daily caffeine intake from the main dietary sources. 
Groups Controls (N = 102) ADPKD (N = 102)
Coffee 115.9 ± 117.9* 74.9 ± 74.5*
Soft drinks 12.5 ± 21.1 6.9 ± 11.2
Chocolate products 3.9 ± 4.6 2.1 ± 4.2
Teas 1.8 ± 5.1 1.6 ± 6.3
Data are reported in mg as means ± SD. Groups: coffee (espres-
so, instant and brewed); soft drinks (cola and guarana); choco-
late products (chocolate powder, dark, semi-sweet, and white 
chocolates); teas (mate and black). ADPKD = autosomal domi-
nant polycystic kidney disease patients. *P < 0.05 compared to 
soft drinks, chocolate products and teas (t-test). 
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= 9) (31 vs 35%, P = 0.681). 
Univariate analysis of all ADPKD patients showed that 
age, hypertension, CKD stage 3 and time since diagnosis 
were significant variables for an association with renal 
volume; however, caffeine intake, protein intake and PRAL 
were not significant (data not shown). Stepwise multiple 
linear regression adjusted for age revealed that the only 
independent variables associated with renal volume were 
the presence of hypertension (P = 0.025), CKD stage 3 (P 
< 0.001) and the time since diagnosis (P = 0.035). 
Another univariate analysis performed with eGFR as 
the dependent variable revealed that age, hypertension 
and protein intake, but not caffeine intake, were associated 
with eGFR (data not shown). However, in the stepwise 
multiple linear regression adjusted for age, the only variable 
associated with eGFR was the presence of hypertension 
(P = 0.003). 
Discussion
Given that caffeine is responsible for PDE inhibition, 
leading to increased levels of cAMP and activating the 
extracellular signal-regulated kinase (ERK) pathway with 
consequent increases in cell proliferation and fluid secre-
tion (18) in ADPKD cystic epithelium, patients with ADPKD 
are being advised to reduce their caffeine consumption 
(8). Data from a cell culture study that showed the effects 
of caffeine on the accumulation of cAMP in cells retrieved 
from renal cysts of ADPKD patients strongly support such 
recommendations (8). However, despite the increases in 
arterial blood pressure induced by chronic caffeine intake in 
a non-orthologous animal model of PKD, no effect on cyst 
development was observed (9). To our knowledge, human 
studies focusing on the caffeine consumption by ADPKD 
patients have not yet been reported. 
Figure 1. A, Pearson’s correlation between log caffeine intake 
and log renal volume. B, Pearson’s correlation between log caf-
feine intake and log estimated glomerular filtration rate (eGFR).
Table 4. Clinical and laboratory characteristics according to caffeine intake. 
Parameters Caffeine intake
0-41.6 mg/day (N = 34) 41.7-98.7 mg/day (N = 34) 98.8-471.4 mg/day (N = 34)
Age (years) 36 ± 12 39 ± 13 43 ± 11
Time since diagnosis (months) 112 ± 103 99 ± 88 101 ± 99
CKD1/2 (N, %) 21 (62) 19 (56) 23 (68)
CKD3 (N, %) 13 (38) 15 (44) 11 (32)
Hypertension (N, %) 16 (47) 26 (76) 22 (65)
Serum creatinine (mg/dL) 1.3 ± 0.73 1.3 ± 0.7 1.4 ± 1.2
eGFR [mL·min-1·(1.73 m2)-1] 74 ± 33 74 ± 35 73 ± 35
Renal volume (mL) 787 (306-3848) 1100 (260-5517) 746 (219-3588)
Parametric variables are reported as means ± SD. Renal volume (nonparametric variable) is reported as median (25th to 
75th percentile). CKD1/2 = chronic kidney disease stages 1/2; CKD3 = chronic kidney disease stage 3; eGFR = estimated 
glomerular filtration rate. No statistically significant differences were detected among tertiles (ANOVA or chi-square test for 
categorical variables).
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Our results showed a low mean caffeine intake by 
ADPKD patients (85.7 mg/day), which was most likely 
due to the awareness of a need for caffeine restriction 
by most of the patients (63%). Since a food history may 
yield imprecise data because this method measures only 
particular days and relies on memory, a 5-step method 
developed by the USDA for collecting 24R was used in 
the current study to minimize misreporting (19). The trend 
of higher prevalence of aware patients (82%) in the first 
tertile of caffeine consumption further supports the view 
that awareness contributed to low caffeine consumption. 
We observed that these patients also had a longer previous 
medical follow-up. However, half of the patients belonging 
to the second and third tertiles were aware of caffeine 
restriction recommendations. These findings suggest that 
not all patients who received some previous dietary advice 
adhered to it. Nevertheless, the aim of the present study 
was not to evaluate compliance, considering that we were 
not the ones to provide dietary recommendations. We hy-
pothesized whether or not “awareness” could interfere with 
the results obtained from the food recalls, and we indeed 
found out that aware patients consumed even less caffeine 
than unaware patients. It must be emphasized that the caf-
feine consumption level was not too high even in the third 
tertile group, where only three patients reported intake of 
more than 300 mg/day. 
The mean daily caffeine consumption by healthy sub-
jects in the present series was somewhat lower (134 mg/
day) than reports in the Brazilian population (171 mg/day) 
(13) and much lower than the estimates from other countries, 
such as the United States (200 mg/day), United Kingdom 
(280 mg/day) and Denmark (490 mg/day) (20). 
In the present series, coffee consumption accounted 
for most of the daily caffeine intake in all groups. These 
findings agree with those for the Brazilian population (12) 
and with American data (20,21), which show that the major 
contributor to caffeine intake in the US population is coffee. 
Conversely, the major source of caffeine intake in the UK 
is tea (20). 
The other purpose of the present study was to determine 
the association between caffeine intake and the clinical 
and laboratory findings in this sample of ADPKD patients. 
An age-adjusted correlation between caffeine intake and 
renal volume was not found in the ADPKD sample. ADPKD 
patients in the highest tertile of caffeine consumption did 
not exhibit a higher median renal volume than the other two 
tertiles. Although the purpose of this cross-sectional study 
was not to verify the impact on disease progression, it is 
well established that renal volume increases with age and 
is directly associated with hypertension, ultimately leading 
to a progressive loss of renal function in the ADPKD setting 
(3). Therefore, a univariate analysis was performed to iso-
late the significant dependent variables, and a multivariate 
linear regression was then used to adjust the bias of these 
interfering factors in kidney enlargement. The stepwise 
multiple linear regression adjusted for age showed that 
renal volume was associated with hypertension, CKD 
stage 3 and the time since diagnosis but not with caffeine 
intake. Given that the protein or ash content of diets has 
been proposed to accelerate the course of ADPKD, we 
evaluated the impact of protein intake and PRAL, which 
provides an estimate of the production of endogenous 
acid that exceeds the level of alkali produced for given 
amounts of foods ingested daily, on kidney volume and 
eGFR (14). Because negative values indicate alkaline foods 
and positive values indicate that the food item has an acid 
load, high-protein diets are usually considered high-PRAL 
diets. Protein intake and PRAL were not associated with 
kidney volume or with eGFR in the present age-adjusted 
multiple regression analysis. Because the main purpose of 
the study was to evaluate the caffeine intake, we did not 
focus on previous instructions regarding protein restric-
tion. Therefore, we could not precisely quantify how many 
patients were following such recommendations. The mean 
protein intake of 1.2 g·kg-1·day-1 (Table 2) certainly shows 
that patients did not reduce their protein intake. However, 
it is worth mentioning that most patients (62%) had a well-
preserved renal function. 
The low level of caffeine consumption found in these 
ADPKD patients might have contributed to the lack of cor-
relation between caffeine intake and renal volume. Although 
the results from cell culture studies cannot be compared 
to our clinical observations, Belibi et al. (8) showed that 10 
to 50 µM caffeine potentiated the effects of desmopressin 
increasing cAMP levels in ADPKD cells. According to these 
investigators, pharmacokinetic studies indicate that the 
ingestion of 1 to 3 cups of coffee leads to plasma caffeine 
levels between 10 and 50 µM; therefore, this amount was 
considered clinically relevant. Because higher levels of caf-
feine would be expected with greater amounts of caffeine, 
leading to greater elevations of renal tissue cAMP, further 
experiments by these investigators used amounts up to 
1000 µM. However, one can argue that such amounts are 
far above the typical human intake. Extrapolations from 
animal studies may not be precise, but the caffeine amount 
that, according to Tanner et al. (9), exacerbated hyperten-
sion but did not change the GFR in Han:SPRD rats was 
equivalent to a human intake of approximately 4 cups of 
coffee per day (380 mg caffeine). In our series, in the range 
of caffeine intake presently disclosed, there was no cor-
relation between caffeine intake and age-adjusted eGFR. 
In addition, the multiple regression analysis revealed that 
hypertension (but not caffeine intake) was the only variable 
associated with the age-adjusted eGFR in ADPKD patients. 
In the aforementioned study (9), greater doses of caffeine, 
equivalent to 9 cups of coffee per day (765 mg caffeine), 
which are far above the human intake, also increased the 
mean arterial pressure with a trend toward a lower GFR 
but did not result in more or larger kidney cysts in this PKD 
model (9). Because caffeine is a weak phosphodiesterase 
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inhibitor (22) and plasma caffeine levels achieved after 
coffee drinking are much lower than those needed to affect 
cAMP breakdown, these investigators (9) proposed the pos-
sibility that caffeine might have affected this disease through 
its effects on arterial pressure and not by changing cAMP, 
although cAMP was not measured in their study. 
One potential limitation of our study is the measurement 
of kidney volume. We are aware that sonography is highly 
operator dependent, lacks accuracy to detect small changes 
in renal volume (23) and that the renal volume measured 
by MRI is more appropriate (24,25), especially when the 
goal is to determine the renal blood flow and progression, 
which was not the focus of the present study. However, MRI 
is not employed in ADPKD patients routinely because of its 
high cost. Despite ultrasound limitations, other investigators 
have shown that determining renal volume by this method 
(26,27) may also be a useful marker for the progression 
of ADPKD.
The cross-sectional nature and sample size of this study 
may be another limitation. Because of the worldwide differ-
ences in caffeine consumption, the methods of preparation 
(regular, espresso or instant), cup sizes and other peculiari-
ties, scientific information about caffeine intake in different 
populations is still warranted. Moreover, due to the lack of 
human data linking coffee intake to worsening of ADPKD, 
observational studies to identify associations between caf-
feine intake with either cysts or renal enlargement in a clinical 
setting should be replicated in larger samples. Additionally, 
the impact of caffeine intake on disease progression was 
not addressed here. 
Nevertheless, several important points must be consid-
ered. Conducting a randomized clinical trial to address the 
role of caffeine restriction in ADPKD seems difficult because 
including a non-restricted control group would be considered 
unethical. Thus far, hypothesis-generating experimental 
studies have already been integrated into clinical practice. 
The premature incorporation of a caffeine restriction policy 
renders longitudinal studies even more difficult to perform 
because awareness has already spread to patients and 
non-health professionals. 
In conclusion, within the range of caffeine consumption 
presently evaluated and considering the limitations of a 
small cross-sectional study, the food-history methodology 
and ultrasound as a method for renal volume measurement, 
no correlation was observed between caffeine intake and 
renal volume or eGFR in ADPKD patients.
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